Search

Your search keyword '"Valery, Patricia"' showing total 921 results
Start Over Author "Valery, Patricia"
921 results on '"Valery, Patricia"'

9. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

Author

Clark, Paul J., Valery, Patricia C., Strasser, Simone I., Weltman, Martin, Thompson, Alexander J., Levy, Miriam, Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Published
2023
Full Text
View/download PDF

17. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Published
2022
Full Text
View/download PDF

20. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C).

Author

Clark, Paul J., Valery, Patricia C., Strasser, Simone I., Weltman, Martin, Thompson, Alex, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Sinclair, Marie, George, Jacob, Sievert, William, MacQuillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Cheng, Wendy, and Roberts, Stuart K.

Subjects
*HEPATIC fibrosis, *CHRONIC hepatitis C, *ALCOHOLISM, *ALCOHOL drinking, *HEPATITIS C virus
Abstract

Introduction: Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct‐acting antiviral (DAA) therapy outcome and the clinical course of liver disease and 2‐year survival for patients receiving HCV DAA therapy. Methods: Adults (n = 2624) recruited from 26 Australian hospital liver clinics during 2016–2021 were followed up for 2 years. Risky alcohol use was defined by a combination of self‐report (≥40 g/day of ethanol), physician‐reported history of problematic alcohol use, and anti‐craving medication prescription via population‐based database linkage. We examined factors associated with advanced liver fibrosis and survival using multivariable logistic and Cox regression. Results: Among 1634 patients (62.3%) with risky alcohol use, 24.6% reported consuming ≥40 g/day of alcohol, 98.3% physician‐reported problematic alcohol use; only 4.1% were dispensed naltrexone/acamprosate. One hundred and forty‐three patients with cirrhosis reported ≥40 g/day of alcohol, 6 (4.3%) were prescribed naltrexone/acamprosate. Risky alcohol use was associated with advanced fibrosis (adjusted‐odds ratio 1.69, 95% confidence interval 1.32–2.17) and patients were over‐represented for cirrhosis (45.1% vs. 25.6% in no‐risky alcohol use [p < 0.001]) and hepatocellular carcinoma (5.7% vs. 2.5% [p < 0.001]). Sustained viral response (p = 0.319) and 2‐year survival (adjusted‐hazard ratio 1.98, 95% confidence interval 0.84–4.63) after DAA therapy were not associated with risky alcohol use. Discussion and Conclusions: Risky alcohol use in HCV patients was prevalent, but did not reduce HCV cure. Treatment for alcohol dependence was low. Risky alcohol use may be under‐recognised in liver clinics. Better integration of addiction medicine into liver services and increased resourcing and addiction medicine training opportunities for hepatologists may help address this. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations.

Author

Gracen, Lucy, Aikebuse, Melanie, Sarraf, Babak, McPhail, Steven M, Russell, Anthony W, O'Beirne, James, Irvine, Katharine M, Williams, Suzanne, Valery, Patricia C, and Powell, Elizabeth E

Subjects
HEPATIC fibrosis, HEALTH impact assessment, TYPE 2 diabetes, FATTY liver, GENERAL practitioners
Abstract

Background: Although clinical guidelines endorse screening for metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis in people with type 2 diabetes (T2D), the feasibility of and barriers and considerations relevant to implementing this approach in the community remain unclear. Methods: Sequential adults with T2D attending selected community clinics during 2021– 2023 were invited to receive a "liver health check" (n=543). A further 95 participants were referred directly from their general practitioner (GP) or self-referred to the study. A total of 302 participants underwent a point of care assessment of hepatic steatosis and stiffness (FibroScan) and were advised to see their GP to discuss the results. "Template" letters containing key results, their interpretation and advice about management of cardiometabolic risk, patient follow-up and referral criteria, were sent to participants' GPs. Results: Referral to a tertiary liver clinic was advised in GP letters for 45 (15%) participants with an increased risk of clinically significant fibrosis (liver stiffness measurement ≥ 8), 15 participants with 'red flags' (eg splenomegaly, thrombocytopenia) and 2 with unsuccessful FibroScan examinations. A referral from GPs to the liver clinic was received for 27 (44%) of these 62 participants. Approximately 90% of GPs rated the "template" letters favourably on a Likert rating scale. Conclusion: The low rate of participation in the "liver health check" and liver clinic referral reflects a real-world scenario and may stem from societal under-recognition and engagement with MASLD, competing health priorities or under-appreciation of the link between liver fibrosis severity and mortality risk. Further studies need to address strategies to enhance participation in liver health assessments and determine their impact on liver-related morbidity/mortality and overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores

Author

Patel, Preya Janubhai, Cheng, Johnson Chieh-Yu, Banh, Xuan, Gracen, Lucy, Radford-Smith, Daniel, Hossain, Fabrina, Horsfall, Leigh Ula, Hayward, Kelly Lee, Williams, Suzanne, Johnson, Tracey, Brown, Nigel Neil, Saad, Nivene, Stuart, Katherine Anne, Russell, Anthony William, Valery, Patricia Casarolli, Clouston, Andrew Donald, Irvine, Katharine Margaret, Bernard, Anne, and Powell, Elizabeth Ellen

Published
2020
Full Text
View/download PDF

26. An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations

Author

Gracen,Lucy, Aikebuse,Melanie, Sarraf,Babak, McPhail,Steven, Russell,Anthony, O’Beirne,James, Irvine,Katharine, Williams,Suzanne, Valery,Patricia, Powell,Elizabeth, Gracen,Lucy, Aikebuse,Melanie, Sarraf,Babak, McPhail,Steven, Russell,Anthony, O’Beirne,James, Irvine,Katharine, Williams,Suzanne, Valery,Patricia, and Powell,Elizabeth

Abstract

Lucy Gracen,1 Melanie Aikebuse,2,3 Babak Sarraf,2– 4 Steven M McPhail,5 Anthony W Russell,6 James O’Beirne,7 Katharine M Irvine,8 Suzanne Williams,9 Patricia C Valery,4,&ast; Elizabeth E Powell2– 4,&ast; 1Department of Gastroenterology and Hepatology, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia; 2Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia; 3Centre for Liver Disease Research, Faculty of Medicine, Translational Research Institute, The University of Queensland, Woolloongabba, QLD, Australia; 4QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; 5Australian Centre for Health Services Innovation School of Public Health, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane, QLD, Australia; 6Endocrinology and Diabetes, the Alfred Hospital, Melbourne, VIC, Australia; 7Department of Gastroenterology and Hepatology, Sunshine Coast University Hospital, Birtinya, QLD, Australia; 8Mater Research, Translational Research Institute, Brisbane, QLD, Australia; 9Inala Primary Care General Practice, Inala, QLD, Australia&ast;These authors contributed equally to this workCorrespondence: Elizabeth E Powell, Centre for Liver Disease Research, Faculty of Medicine, Translational, Research Institute, The University of Queensland, Level 5, West Wing, 37, Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia, Tel +61 412 014 337, Email e.powell@uq.edu.auBackground: Although clinical guidelines endorse screening for metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis in people with type 2 diabetes (T2D), the feasibility of and barriers and considerations relevant to implementing this approach in the community remain unclear.Methods: Sequential adults with T2D attending selected community clinics during 2021– 2023 were invited to receive a “liver health check” (n=543). A further 95 particip

Published
2024

27. A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults

Author

Black, Lucinda J, Baker, Kimberley, Ponsonby, Anne-Louise, van der Mei, Ingrid, Lucas, Robyn M, Pereira, Gavin, Chapman, Caron, Dr, Coulthard, Alan, Prof, Dear, Keith, Prof, Dwyer, Terry, Prof, Kilpatrick, Trevor, Prof, Lucas, Robyn, Prof, McMichael (dec), Tony, Prof, Pender, Michael P, Prof, Ponsonby, Anne-Louise, Prof, Taylor, Bruce, Prof, Valery, Patricia, A/Prof, van der Mei, Ingrid, A/Prof, and Williams, David, Dr

Published
2019
Full Text
View/download PDF

29. A parallel randomised trial testing community fibrosis assessment for suspected non-alcoholic fatty liver disease: Outcomes from LOCATE-NAFLD

Author

Tulleners, Ruth, primary, Barnett, Adrian, additional, O'Beirne, James, additional, Powell, Elizabeth, additional, Hickman, Ingrid, additional, Valery, Patricia, additional, Kularatna, Sanjeewa, additional, Stuart, Katherine, additional, McIvor, Carolyn, additional, Witness, Elen, additional, Aikebuse, Melanie, additional, and Brain, David, additional

Published
2024
Full Text
View/download PDF

30. Australians with metabolic dysfunction‐associated steatotic liver disease have a twofold increase in the incidence of cancer.

Author

Powell, Elizabeth E, Roche, Shruti, Sarraf, Babak, Hartel, Gunter, Skoien, Richard, Leggett, Barbara, O'Beirne, James, and Valery, Patricia C

Subjects
LIVER diseases, TYPE 2 diabetes, CONSCIOUSNESS raising, STOMACH cancer, DISEASE risk factors
Abstract

Background and Aim: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with an increased risk of extrahepatic morbidity. We compared the incidence of cancers in adults admitted to Queensland hospitals with MASLD with that for the Queensland population and examined the association between cirrhosis and type 2 diabetes and the development of extrahepatic cancers. Methods: In this retrospective study, we identified all cancers (Queensland Cancer Registry) after the first hospitalization with MASLD during Jul‐2007 to Dec‐2019, estimated age‐standardized incidence (ASI) of cancers, and compared that with the ASI in the Queensland population (incidence rate ratios [IRR]). Among the MASLD cohort, we examined the association between diabetes and cancer risk (Cox regression). Median follow‐up was 3.8 years (54 204 person‐years). Results: Totally 1104 new cancers were diagnosed in 1018 patients (8.9% of 9771 non‐cirrhotic and 1712 adults with cirrhosis). The ASI (all cancers) of 1668.2 per 100 000 person‐years in men (95% CI 1523.7–1827.4) and 1284.0 per 100 000 person‐years in women (95% CI 1169.6–1408.2) was 2‐fold higher than that of the Queensland population (IRR = 1.94, 95% CI 1.75–2.16 and IRR = 1.99, 95% CI 1.78–2.22, respectively). Incidence of stomach cancer, unknown primary, and pancreas was 3‐ to 5‐fold higher compared to the general population (all P < 0.001). In multivariable analysis of the MASLD cohort, older age (e.g. ≥70 years adjusted hazard ratio [adj‐HR] = 4.59, 95% CI 3.61–5.83), male gender (adj‐HR = 1.20, 95% CI 1.05–1.37), and cirrhosis (adj‐HR = 1.37, 95% CI 1.11–1.70) were independently associated with extrahepatic cancer risk, while diabetes was not. Conclusions: Our findings will help to raise awareness among clinicians about the importance of cancer vigilance in this patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care

Author

Clark, Paul J, primary, Valery, Patricia C, additional, Strasser, Simone I, additional, Weltman, Martin, additional, Thompson, Alex, additional, Levy, Miriam T, additional, Leggett, Barbara, additional, Zekry, Amany, additional, Rong, Julian, additional, Sinclair, Marie, additional, George, Jacob, additional, Bollipo, Steven, additional, McGarity, Bruce, additional, Sievert, William, additional, MacQuillan, Gerry, additional, Tse, Edmund, additional, Nicoll, Amanda, additional, Wade, Amanda, additional, Cheng, Wendy, additional, and Roberts, Stuart K, additional

Published
2023
Full Text
View/download PDF

41. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.

Author

Clark, Paul J, Valery, Patricia C, Strasser, Simone I, Weltman, Martin, Thompson, Alex, Levy, Miriam T, Leggett, Barbara, Zekry, Amany, Rong, Julian, Sinclair, Marie, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, MacQuillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Cheng, Wendy, and Roberts, Stuart K

Subjects
*CHRONIC hepatitis C, *HEPATITIS C, *MENTAL illness, *DRUG abuse, *CONTINUUM of care, *DRUG abuse treatment
Abstract

Background: Direct‐acting antiviral (DAA) therapies for hepatitis C virus infection (HCV) lead to excellent rates of sustained virological response (SVR). However, loss to follow‐up (LTFU) for SVR testing remains a challenge. We examine factors associated with LTFU in a real‐world setting. Methods: Adults who received DAA therapy for HCV in one of 26 centers across Australia during 2016–2021 were followed up for 2 years. Data sources included the patient medical records and the national Pharmaceutical and Medicare Benefits Schemes. Linkage to Medicare provided utilization data of other health‐care providers and re‐treatment with DAAs. LTFU was defined as no clinic attendance for SVR testing by at least 52 weeks after DAA treatment commencement. Multivariable logistic regression assessed factors associated with LTFU. Results: In 3619 patients included in the study (mean age 52.0 years; SD = 10.5), 33.6% had cirrhosis (69.4% Child–Pugh class B/C), and 19.3% had HCV treatment prior to the DAA era. Five hundred and fifteen patients (14.2%) were LTFU. HCV treatment initiation in 2017 or later (adj‐OR = 2.82, 95% confidence interval [CI] 2.25–3.54), younger age (adj‐OR = 2.63, 95% CI 1.80–3.84), Indigenous identification (adj‐OR = 1.99, 95% CI 1.23–3.21), current injection drug use or opioid replacement therapy (adj‐OR = 1.66, 95% CI 1.25–2.20), depression treatment (adj‐OR = 1.49, 95% CI 1.17–1.90), and male gender (adj‐OR = 1.31, 95% CI 1.04–1.66) were associated with LTFU. Conclusions: These findings stress the importance of strengthening the network of providers caring for patients with HCV. In particular, services targeting vulnerable groups of patients such as First Nations Peoples, youth health, and those with addiction and mental health disorders should be equipped to treat HCV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Low Prevalence of Use of Allied Health and Community Services for Patients with Cirrhosis in Australia: A Need for Greater Engagement

Author

Powell,Elizabeth E, Stuart,Katherine A, Finnigan,Simon, Hinson,Jan, Bernardes,Christina M, Hartel,Gunter, Valery,Patricia C, Powell,Elizabeth E, Stuart,Katherine A, Finnigan,Simon, Hinson,Jan, Bernardes,Christina M, Hartel,Gunter, and Valery,Patricia C

Abstract

Elizabeth E Powell,1,2 Katherine A Stuart,1 Simon Finnigan,3 Jan Hinson,4 Christina M Bernardes,5 Gunter Hartel,6 Patricia C Valery2,5 1Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; 2Centre for Liver Disease Research, Faculty of Medicine, the University of Queensland, Woolloongabba, Queensland, Australia; 3Community and Oral Health, Metro North Health, Chermside, Queensland, Australia; 4Faculty of Health Sciences, School of Allied Health, Australian Catholic University, Banyo, Queensland, Australia; 5Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; 6Statistics, QIMR Berghofer Medical Research Institute, Herston, Queensland, AustraliaCorrespondence: Patricia C Valery, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia, Tel +61 07 3362 0376, Email Patricia.Valery@qimrberghofer.edu.auBackground: Psychosocial, lifestyle and practical needs are not routinely attended to during outpatient hepatology management, and little is known about the type and effectiveness of support services accessed by patients with cirrhosis. We quantified the type and use of community and allied health services in patients with cirrhosis.Methods: The study included 562 Australian adults with a diagnosis of cirrhosis. Health service use was assessed via questionnaire and via linkage to the Australian Medicare Benefits Schedule. Patient needs were assessed using the Supportive Needs Assessment tool for Cirrhosis (SNAC).Results: Although most patients (85.9%) used at least one community/allied health service for support with their liver disease, many reported requiring additional help with psychosocial (67.4%), lifestyle (34.3%) or practical needs (21.9%) that were not met by available services, or patients did not access services. A multidisciplinary care plan or case conference (in the 12 months prior to recruitment) was access

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results